Diabetes care company Eli Lilly and Company (NYSE:LLY) reported on Friday the receipt of approval from US Food and Drug Administration (FDA) for Trulicity for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes.
Trulicity (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce the risk of MACE for both primary and secondary prevention type 2 diabetes patients who have established cardiovascular (CV) disease or multiple cardiovascular risk factors.
Additionally, Trulicity 1.5 mg, a weekly glucagon-like peptide 1 receptor agonist (GLP-1 RA), compared to placebo, is both added to standard of care (according to local standard of care guidelines), on cardiovascular (CV) events in adults with type 2 diabetes, added the company.
REWIND, the company's cardiovascular multicenter, randomized, double-blind, placebo-controlled outcomes trial of Trulicity (dulaglutide) in 1.5 mg, showed a significant risk reduction in MACE, a composite endpoint of nonfatal myocardial infarction (heart attack), nonfatal stroke or CV death, disclosed the company.
Since 2014, Trulicity has been available in the US and is the number one prescribed GLP-1 RA. In addition to its proven glycemic efficacy and easy-to-use device, it can now be prescribed to help people with type 2 diabetes reduce their risk of CV events, concluded the company.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes